FilingReader Intelligence

Fosun Pharma invests RMB 1.2bn in nuclear medicine subsidiary

July 22, 2025 at 05:10 PM UTC•By FilingReader AI

Fosun Pharma will establish "Xingrui Jingxuan" with co-investors, contributing RMB 1.2 billion for an 89.9% stake to expand its nuclear medicine capabilities.

The company completed a share repurchase program, buying back 14.2 million A-shares and 3.4 million H-shares for RMB 348 million and HK$48 million respectively.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

Primary Source Document

Announcement by Fosun Pharma regarding the establishment of a new controlling subsidiary, the implementation of a co-investment and incentive plan, and a connected transactionJuly 22, 2025 at 08:00 AM UTC

Supplementary Source Documents

Fosun Pharma's announcement regarding the results of the share repurchase implementation and changes in shareholding structureJuly 22, 2025 at 08:00 AM UTC

Shanghai Fosun Pharmaceutical Group

SSE:600196•Shanghai Stock Exchange

PharmaceuticalsShanghai Blue Chip

RSS feed for Shanghai Fosun Pharmaceutical Group

News Alerts

Get instant email alerts when Shanghai Fosun Pharmaceutical Group publishes news

Free account required • Unsubscribe anytime

Browse RSS Feeds

Filing Activity Timeline

View Complete Filing History →